Show simple item record

dc.creatorMcCubrey, James A
dc.creatorSteelman, Linda S
dc.creatorKempf, C Ruth
dc.creatorChappell, William H
dc.creatorAbrams, Stephen L
dc.creatorStivala, Franca
dc.creatorMalaponte, Graziella
dc.creatorNicoletti, Ferdinando
dc.creatorLibra, Massimo
dc.creatorBaesecke, Joerg
dc.creatorMaksimović-Ivanić, Danijela
dc.creatorMijatović, Sanja
dc.creatorMontalto, Giuseppe
dc.creatorCervello, Melchiorre
dc.creatorCocco, Lucio
dc.creatorMartelli, Alberto M
dc.date.accessioned2017-11-23T11:08:34Z
dc.date.available2015-11-17T10:26:51Z
dc.date.issued2011sr
dc.identifier.issn0021-9541sr
dc.identifier.otherRad_konverzija_3247sr
dc.identifier.urihttps://ibiss-r.rcub.bg.ac.rs/handle/123456789/1252
dc.description.abstractChemotherapy remains a commonly used therapeutic approach for many cancers. Indeed chemotherapy is relatively effective for treatment of certain cancers and it may be the only therapy (besides radiotherapy) that is appropriate for certain cancers. However, a common problem with chemotherapy is the development of drug resistance. Many studies on the mechanisms of drug resistance concentrated on the expression of membrane transporters and how they could be aberrantly regulated in drug resistant cells. Attempts were made to isolate specific inhibitors which could be used to treat drug resistant patients. Unfortunately most of these drug transporter inhibitors have not proven effective for therapy. Recently the possibilities of more specific, targeted therapies have sparked the interest of clinical and basic researchers as approaches to kill cancer cells. However, there are also problems associated with these targeted therapies. Two key signaling pathways involved in the regulation of cell growth are the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways. Dysregulated signaling through these pathways is often the result of genetic alterations in critical components in these pathways as well as mutations in upstream growth factor receptors. Furthermore, these pathways may be activated by chemotherapeutic drugs and ionizing radiation. This review documents how their abnormal expression can contribute to drug resistance as well as resistance to targeted therapy. This review will discuss in detail PTEN regulation as this is a critical tumor suppressor gene frequently dysregulated in human cancer which contributes to therapy resistance. Controlling the expression of these pathways could improve cancer therapy and ameliorate human health.en
dc.description.sponsorship[MinSan 2008]sr
dc.language.isoEnglishsr
dc.rightsrestrictedAccess
dc.sourceJournal of Cellular Physiologysr
dc.titleTherapeutic Resistance Resulting From Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathwaysen
dc.typereview
dc.rights.licenseARR
dcterms.abstractЦервелло, Мелцхиорре; Максимовић-Иванић, Данијела Д.; Мијатовић, Сања A.; МцЦубреy, Јамес A; Стеелман, Линда С; Кемпф, Ц Рутх; Цхаппелл, Wиллиам Х; Aбрамс, Степхен Л; Стивала, Франца; Малапонте, Гразиелла; Ницолетти, Фердинандо; Либра, Массимо; Баесецке, Јоерг; Монталто, Гиусеппе; Цоццо, Луцио; Мартелли, Aлберто М;
dc.rights.holder© 2011 Wiley-Liss, Inc.
dc.citation.issue11sr
dc.citation.volume226sr
dc.identifier.doi10.1002/jcp.22647
dc.identifier.pmid21302297
dc.identifier.scopus2-s2.0-79960237399
dc.identifier.wos000295234800005
dc.citation.epage2781sr
dc.type.versionpublishedVersionen
dc.citation.rankM21


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record